Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer.
Bianco
A R
AR
Division of Medical Oncology, School of Medicine, University Federico II, Naples, Italy.
De Placido
S
S
Perrone
F
F
Carlomagno
C
C
De Laurentiis
M
M
Del Mastro
L
L
Lauria
R
R
Marinelli
A
A
Gallo
C
C
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010052:Ovariectomy; D017698:Postmenopause; D017697:Premenopause; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012189:Retrospective Studies; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D003520:Cyclophosphamide; D008558:Melphalan; D005472:Fluorouracil; D008727:Methotrexate